MedDataX Logo

Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers

NCT ID: NCT01638598

Last Updated: 2013-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety,tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1021958 after single rising doses (SRD) in healthy Asian male volunteers

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 1021958 dose group 1

subject to receive a tablet containing dose group 1 BI 1021958 single dose

Group Type EXPERIMENTAL

Test drug

Intervention Type DRUG

BI 1021958

matching placebo

Intervention Type DRUG

matching placebo in each dose level

BI 1021958 dose group 2

subject to receive a tablet containing dose group 2 BI 1021958 single dose

Group Type EXPERIMENTAL

matching placebo

Intervention Type DRUG

matching placebo in each dose level

Test drug

Intervention Type DRUG

BI 1021958

BI 1021958 dose group 3

subject to receive a tablet containing dose group 3 BI 1021958 single dose

Group Type EXPERIMENTAL

Test drug

Intervention Type DRUG

BI 1021958

matching placebo

Intervention Type DRUG

matching placebo in each dose level

BI 1021958 dose group 4

subject to receive a tablet containing dose group 4 BI 1021958 single dose

Group Type EXPERIMENTAL

matching placebo

Intervention Type DRUG

matching placebo in each dose level

Test drug

Intervention Type DRUG

BI 1021958

BI 1021958 dose group 5

subject to receive a tablet containing dose group 5 BI 1021958 single dose

Group Type EXPERIMENTAL

Test drug

Intervention Type DRUG

BI 1021958

matching placebo

Intervention Type DRUG

matching placebo in each dose level

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

matching placebo

matching placebo in each dose level

Intervention Type DRUG

Test drug

BI 1021958

Intervention Type DRUG

matching placebo

matching placebo in each dose level

Intervention Type DRUG

Test drug

BI 1021958

Intervention Type DRUG

Test drug

BI 1021958

Intervention Type DRUG

Test drug

BI 1021958

Intervention Type DRUG

Test drug

BI 1021958

Intervention Type DRUG

matching placebo

matching placebo in each dose level

Intervention Type DRUG

matching placebo

matching placebo in each dose level

Intervention Type DRUG

matching placebo

matching placebo in each dose level

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy males based upon a complete medical history, including a physical examination, vital signs (blood pressure, pulse rate), 12-lead ECG, and clinical laboratory tests
2. Chinese ethnicity, Japanese ethnicity according to the following criteria Japanese; born in Japan, be a current Japanese passport holder, have lived outside of Japan \<5 years, and have parents and grandparents who were all born in Japan Chinese; ethnic Chinese, born in China or ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese grandparents who were all born in China
3. Age within the range of 20 to 45 years
4. Body mass index within the range of 18.5 and 25 kg/m2
5. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.

Exclusion Criteria

1. Any finding of the medical examination (including Blood Pressure, Pulse Rate, ECG and Safety laboratory) deviating from normal and of clinical relevance
2. Any evidence of a clinically relevant concomitant disease
3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
4. Surgery of the gastrointestinal tract (except appendectomy)
5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
6. History of relevant orthostatic hypotension, fainting spells or blackouts.
7. Chronic or relevant acute infections
8. History of relevant allergy/hypersensitivity (including allergy/hypersensitivity to the study drug or its excipients)
9. Intake of drugs with a long half-life (more than 24 hours) within at least 1 month or less than 10 half-lives of the respective drug prior to administration
10. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval (based on the knowledge at the time of protocol preparation) within 10 days prior to administration
11. Participation in another trial with an investigational drug administration within 2 months prior to administration
12. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)
13. Inability to refrain from smoking on trial days
14. Alcohol abuse (more than 30 g/day)
15. Drug abuse
16. Blood donation (more than 100 mL within 4 weeks prior to administration)
17. Any laboratory value outside the reference range that is of clinical relevance
18. Inability to comply with dietary regimen of trial site
19. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval more than 450 ms), heart rate outside 45 to 90 bpm, or any other relevant ECG findings at screening
20. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of long QT Syndrome)
21. Subjects considered unsuitable for inclusion by the investigator, e.g. because considered not able to understand and comply with study requirements, or have any condition which in the opinion of the investigator would not allow safe participation in the study
Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1310.3.8201 Boehringer Ingelheim Investigational Site

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1310.3

Identifier Type: -

Identifier Source: org_study_id